Good afternoon everyone and thank you for joining us today. Chris?Ĭhristopher Anzalone - President and Chief Executive Officer With that said, I'd like to turn the call over to Cris Anzalone, President and CEO of the company. You should refer to the discussions under Risk Factors in Arrowhead's annual report on Form 10-K and the company's subsequent quarterly reports on Form 10-Q for additional matters to be considered in this regard, including risks and other considerations that could cause actual results to vary from the presently expected results expressed in today's call.
#ARWR CONVERSATIONS UPDATE#
Arrowhead disclaims any intent and undertakes no duty to update any of the forward-looking statements discussed on today's call.
Thus, actual results may differ materially. These statements represent management's current expectations and are inherently uncertain. These include statements regarding our expectations around the development, safety and efficacy of our drug candidates, projected cash runway and expected future development and commercialization activities. All statements other than statements of historical fact, including without limitation those with respect to Arrowhead's goals, plans and strategies are forward-looking statements.
James Hamilton, who was recently promoted to Senior Vice President and Head of Discovery & Translational Medicine will both be available during the Q&A session of today's call.īefore we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. In addition, James Hassard, our Chief Commercial Officer and Dr. Javier San Martin, Chief Medical Officer, who will discuss our clinical programs and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. Christopher Anzalone who will provide an overview of the quarter Dr. With us today from management are President and CEO, Dr. Good afternoon everyone and thank you for joining us today to discuss Arrowhead's results for its fiscal year ended September 30, 2020.